News Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Real-time Estimate Cboe BZX Other stock markets 12:43:25 2024-04-16 pm EDT			5-day change	1st Jan Change
29.36 ^USD	+0.36%		-1.43%	+31.50%

Feb. 16	RBC Trims Price Target on Agios Pharmaceuticals to $42 From $43, Keeps Outperform Rating	MT
Feb. 15	Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Agios Publishes 2024 Environmental, Social and Governance Report	Apr. 10	AQ
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report	Apr. 09	AQ
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024	Mar. 06	AQ
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024	Mar. 05	AQ
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024	Feb. 22	AQ
RBC Trims Price Target on Agios Pharmaceuticals to $42 From $43, Keeps Outperform Rating	Feb. 16	MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Agios Pharmaceuticals 2023 Loss Widens, Revenue Rises	Feb. 15	MT
Transcript : Agios Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	Feb. 15	AQ
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024	Feb. 02	AQ
Transcript : Agios Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM	Jan. 10
Agios Pharmaceuticals Insider Sold Shares Worth $277,397, According to a Recent SEC Filing	Jan. 09	MT
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio	Jan. 08	AQ
Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio	Jan. 08	CI
Agios Pharmaceuticals Shares Jump Pre-Bell as Phase 3 Study on Blood Disorder Treatment Meets Endpoints	Jan. 03	MT
Agios Pharmaceuticals : ENERGIZE Phase 3 Topline Results	Jan. 03	PU
Agios' blood disorder drug meets goals of late-stage study	Jan. 03	RE
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia	Jan. 03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Summary

Filters